SE8901593D0 - Laangtidsverkande diklofenak-natrium-preparat - Google Patents

Laangtidsverkande diklofenak-natrium-preparat

Info

Publication number
SE8901593D0
SE8901593D0 SE8901593A SE8901593A SE8901593D0 SE 8901593 D0 SE8901593 D0 SE 8901593D0 SE 8901593 A SE8901593 A SE 8901593A SE 8901593 A SE8901593 A SE 8901593A SE 8901593 D0 SE8901593 D0 SE 8901593D0
Authority
SE
Sweden
Prior art keywords
diclofenac
diclofenac sodium
long
release
diclofenak
Prior art date
Application number
SE8901593A
Other languages
English (en)
Other versions
SE509029C2 (sv
SE8901593L (sv
Inventor
M Okada
Original Assignee
Ss Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ss Pharmaceutical Co filed Critical Ss Pharmaceutical Co
Publication of SE8901593D0 publication Critical patent/SE8901593D0/sv
Publication of SE8901593L publication Critical patent/SE8901593L/sv
Publication of SE509029C2 publication Critical patent/SE509029C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8901593A 1988-08-16 1989-05-03 Långtidsverkande diklofenak-natriumpreparat SE509029C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20349888 1988-08-16

Publications (3)

Publication Number Publication Date
SE8901593D0 true SE8901593D0 (sv) 1989-05-03
SE8901593L SE8901593L (sv) 1990-12-06
SE509029C2 SE509029C2 (sv) 1998-11-30

Family

ID=16475153

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8901593A SE509029C2 (sv) 1988-08-16 1989-05-03 Långtidsverkande diklofenak-natriumpreparat

Country Status (13)

Country Link
US (1) US4968505A (sv)
JP (1) JPH07116028B2 (sv)
KR (1) KR950003610B1 (sv)
BE (1) BE1002710A5 (sv)
CA (1) CA1319616C (sv)
CH (1) CH678813A5 (sv)
DE (1) DE3915150C2 (sv)
FR (1) FR2635460B1 (sv)
GB (1) GB2221842B (sv)
HK (1) HK48194A (sv)
IT (1) IT1231517B (sv)
NL (1) NL194882C (sv)
SE (1) SE509029C2 (sv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5079001A (en) * 1989-11-03 1992-01-07 Ciba-Geigy Corporation Liquid oral formulation of diclofenac
US5015481A (en) * 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US5518737A (en) * 1991-10-16 1996-05-21 Orion-Yhtyma Oy Peroral drug delivery system
WO1994003160A1 (en) * 1992-08-05 1994-02-17 F.H. Faulding & Co. Limited Pelletised pharmaceutical composition
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
DE4403943A1 (de) 1994-02-08 1995-08-10 Hexal Pharma Gmbh Orale Azrneimittelzubereitung mit Diclofenac-Natrium
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
EP1690531A3 (en) * 1996-09-30 2010-01-20 Alza Corporation Dosage form and method for administering drug
CN1231603A (zh) * 1996-09-30 1999-10-13 阿尔萨公司 剂型和施药方法
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
ES2129356B1 (es) * 1997-03-26 2000-01-16 Pierre Fabre Iberica S A Forma farmaceutica de liberacion prolongada y procedimiento para su o btencion.
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
EP1110553B1 (en) * 1998-08-10 2013-03-27 Asahi Kasei Pharma Corporation Sustained release oral preparations of fasudil hydrochloride
EA200300128A1 (ru) * 2000-08-10 2003-08-28 Юнихарт Корпорейшн Фармацевтические композиции, содержащие карбонат лития
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
WO2012169614A1 (ja) * 2011-06-10 2012-12-13 ニプロ株式会社 口腔内崩壊錠の製造方法
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
EP3377046A1 (en) * 2015-11-17 2018-09-26 Rontis Hellas S.A. Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
CN114306260B (zh) * 2021-12-29 2023-10-24 濮阳市汇元药业有限公司 一种新型双氯芬酸钠片及其制备方法
DE202022100544U1 (de) 2022-01-31 2022-02-16 Ranjitsing Babasing Bayas Neue orale Streifen- oder Dünnfilmform von Diclofenac-Natrium

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
CH655507B (sv) * 1983-01-12 1986-04-30
DE3328401A1 (de) * 1983-08-05 1985-02-21 Merckle GmbH, 7902 Blaubeuren Injizierbare loesung zur behandlung von entzuendungen
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
CH664085A5 (de) * 1985-02-08 1988-02-15 Ciba Geigy Ag Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung.
JPS61280426A (ja) * 1985-06-04 1986-12-11 Ikeda Mohandou:Kk 消炎鎮痛用貼付剤
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
CH675537A5 (sv) * 1988-03-25 1990-10-15 Ciba Geigy Ag

Also Published As

Publication number Publication date
JPH02237918A (ja) 1990-09-20
JPH07116028B2 (ja) 1995-12-13
CH678813A5 (sv) 1991-11-15
IT8948030A0 (it) 1989-06-01
NL8901200A (nl) 1990-03-16
DE3915150A1 (de) 1990-03-01
KR950003610B1 (ko) 1995-04-17
BE1002710A5 (fr) 1991-05-14
GB2221842B (en) 1991-10-16
GB2221842A (en) 1990-02-21
NL194882C (nl) 2003-06-04
IT1231517B (it) 1991-12-07
US4968505A (en) 1990-11-06
FR2635460B1 (fr) 1994-09-16
FR2635460A1 (fr) 1990-02-23
HK48194A (en) 1994-05-27
KR900002769A (ko) 1990-03-23
NL194882B (nl) 2003-02-03
GB8910271D0 (en) 1989-06-21
CA1319616C (en) 1993-06-29
DE3915150C2 (de) 1997-04-17
SE509029C2 (sv) 1998-11-30
SE8901593L (sv) 1990-12-06

Similar Documents

Publication Publication Date Title
SE8901593L (sv) Laangtidsverkande diklofenak-natrium-preparat
LV12399A (lv) Uzlabotas vienreiz diena lietojamas pulsejosas miniciklina mogades sistemas
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
FI873225A (sv) Förfarande för framställning av en oral, galenisk naproxenkomposition från vilken det aktiva ämnet frigörs på ett programmerat sätt
CZ277718B6 (en) Transdermal therapeutic system
FI885460A (sv) Förfarande för framställning av en farmaceutisk sammansättning för oral administration och med reglerad frisättning av det aktiva ämnet
FI96273B (sv) Förfarande för framställning av läkemedels kontrollerat frigörande dosform
DE3686936T2 (de) Am zielorgan wirkendes enterales abgabesystem.
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
DE3750145D1 (de) Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
DK0427247T3 (da) Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel
DE69928554D1 (de) Therapeutische formulierung enthaltende dosierungsform
DE3856258T2 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
DE69021405D1 (de) System zur gesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu dessen Herstellung.
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
ATE104146T1 (de) Zubereitung mit verzoegerter freigabe eines hydrochlorids eines basischen arzneistoffs.
ATE57913T1 (de) Catechinamide, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zubereitung.
Krechniak et al. Effect of selected pyrethroids on cholinesterase activity in rat.
RS50053B (sr) Oksikodonski preparati koji se kontrolisano ispuštaju

Legal Events

Date Code Title Description
NUG Patent has lapsed